RxDoctor Payments Data

Nabil Mesiha, MD

Critical Care Medicine · Pennington, NJNPI 1932512175

Payments from drug & device makers

$213in general payments, 2019–2025

Across 8 payments — averaging $26.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viatris Specialty LLC$59
  • Boehringer Ingelheim$44
  • Shionogi Inc$32
  • AstraZeneca$29
  • Genentech USA, Inc.$27
  • GSK$22

What the payments were for

  • Food & beverage$213100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$213 in reported general payments places this provider in the 30th percentile of 254 critical care medicine providers in New Jersey.

See all critical care medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$126,674
Medicare patients
330
Services billed
1,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter184$140,008
Breo ElliptaFluticasone/Vilanterol71$36,720
Incruse ElliptaUmeclidinium Bromide76$27,762
Albuterol Sulfate HfaAlbuterol Sulfate403$12,034
Spiriva HandihalerTiotropium Bromide18$8,928
Spiriva RespimatTiotropium Bromide15$7,674
SymbicortBudesonide/Formoterol Fumarate28$7,058
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate33$5,826
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$4,779
Roflumilast18$1,652
Wixela InhubFluticasone Propion/Salmeterol11$1,578
Ventolin HfaAlbuterol Sulfate19$1,269
Montelukast Sodium95$919
Fluticasone Propionate41$387
Prednisone63$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$22$204,490331 claims
Boehringer IngelheimSpiriva Respimat$44$7,67415 claims
AstraZenecaSymbicort$29$7,05828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 254 critical care medicine providers in New Jersey.

Other critical care medicine in Pennington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →